CDK4 and gastrointestinal stromal tumor: Building on these findings, this study, along with prior research,32 suggests that CDK4/6–cyclin D1–Rb pathway is a promising therapeutic target not only for KIT‐independent GIST but also for KIT‐mutant GIST.54